You can buy or sell Insmed and other stocks, options, ETFs, and crypto commission-free!
Insmed, Inc. Common Stock, also called Insmed, is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Read More Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Bridgewater, New Jersey
52 Week High
52 Week Low
Seeking AlphaMay 24
Insmed closes $250M capital raise
Insmed (INSM +0.6% ) has closed its public offering of ~9.6M common shares at $26 per share. Gross proceeds were ~$250M. Underwriters have a 30-day option to buy up to an additional ~1M shares from the company and up to 400K shares from Chairman & CEO William Lewis....
Seeking AlphaMay 20
Insmed's Arikayce shows sustained benefit in late-stage lung disease study
New data from a Phase 3 clinical trial, CONVERT, evaluating Insmed's (NASDAQ:INSM) ARIKAYCE (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease showed a durable treatment effect when added to guideline-based therapy (GBT) compared to GBT alone.
The Motley FoolMay 8
Insmed (INSM) Q1 2019 Earnings Call Transcript
Insmed (NASDAQ:INSM) Q1 2019 Earnings Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Insmed conference call to discuss the company's first-quarter financial results. [Operator instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Blaine Davis, head of investor relations. You may begin. Blaine Davis -- He...
Expected Aug 1, Pre-Market